DE2322361A1 - Pyranonderivate und verfahren zu ihrer herstellung - Google Patents
Pyranonderivate und verfahren zu ihrer herstellungInfo
- Publication number
- DE2322361A1 DE2322361A1 DE2322361A DE2322361A DE2322361A1 DE 2322361 A1 DE2322361 A1 DE 2322361A1 DE 2322361 A DE2322361 A DE 2322361A DE 2322361 A DE2322361 A DE 2322361A DE 2322361 A1 DE2322361 A1 DE 2322361A1
- Authority
- DE
- Germany
- Prior art keywords
- alkyl
- pyranone
- methyl
- straight
- branched chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims description 21
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical class O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 title claims description 11
- 238000004519 manufacturing process Methods 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 12
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 7
- 150000001412 amines Chemical class 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- ZMONSKDPLONLID-UHFFFAOYSA-N 2-methyl-3-(oxiran-2-ylmethoxy)pyran-4-one Chemical compound O1C=CC(=O)C(OCC2OC2)=C1C ZMONSKDPLONLID-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 3
- LKNWBCGCGZYUGC-UHFFFAOYSA-N 3-[3-(tert-butylamino)-2-hydroxypropoxy]-2-methylpyran-4-one Chemical compound CC=1OC=CC(=O)C=1OCC(O)CNC(C)(C)C LKNWBCGCGZYUGC-UHFFFAOYSA-N 0.000 claims 1
- 150000002118 epoxides Chemical class 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- -1 3- (3-substituted-amino-2 -hydroxypropoxy) -2-substituted-4-pyranones Chemical class 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 3
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000002876 beta blocker Substances 0.000 description 3
- KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229940039009 isoproterenol Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WREHPEFXXFJIIJ-UHFFFAOYSA-N 1-(1h-indol-3-yl)-2-methylpropan-2-amine Chemical compound C1=CC=C2C(CC(C)(N)C)=CNC2=C1 WREHPEFXXFJIIJ-UHFFFAOYSA-N 0.000 description 1
- KWTSXDURSIMDCE-UHFFFAOYSA-N 1-phenylpropan-2-amine Chemical compound CC(N)CC1=CC=CC=C1 KWTSXDURSIMDCE-UHFFFAOYSA-N 0.000 description 1
- 125000004898 2,2-dimethylpropylamino group Chemical group CC(CN*)(C)C 0.000 description 1
- CMEMXCFYJKGOMS-UHFFFAOYSA-N 2-benzyl-3-hydroxypyran-4-one Chemical compound O1C=CC(=O)C(O)=C1CC1=CC=CC=C1 CMEMXCFYJKGOMS-UHFFFAOYSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
- DWAFWTJANIITML-UHFFFAOYSA-N 3-hydroxy-2-propylpyran-4-one Chemical compound CCCC=1OC=CC(=O)C=1O DWAFWTJANIITML-UHFFFAOYSA-N 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NCIKQJBVUNUXLW-UHFFFAOYSA-N N-methyltryptamine Chemical compound C1=CC=C2C(CCNC)=CNC2=C1 NCIKQJBVUNUXLW-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000220304 Prunus dulcis Species 0.000 description 1
- VOLMSPGWNYJHQQ-UHFFFAOYSA-N Pyranone Natural products CC1=C(O)C(=O)C(O)CO1 VOLMSPGWNYJHQQ-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
- C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA141,469A CA989848A (en) | 1972-05-05 | 1972-05-05 | 3-(3-substituted amino-2-hydroxypropoxy)-2-substituted-4-pyranones and process for preparing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2322361A1 true DE2322361A1 (de) | 1973-11-22 |
Family
ID=4093187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2322361A Withdrawn DE2322361A1 (de) | 1972-05-05 | 1973-05-03 | Pyranonderivate und verfahren zu ihrer herstellung |
Country Status (13)
-
1972
- 1972-05-05 CA CA141,469A patent/CA989848A/en not_active Expired
-
1973
- 1973-04-16 SE SE7305382A patent/SE396605B/xx unknown
- 1973-04-18 NL NL7305478A patent/NL7305478A/xx not_active Application Discontinuation
- 1973-04-27 AU AU54938/73A patent/AU473061B2/en not_active Expired
- 1973-04-30 GB GB2047673A patent/GB1390486A/en not_active Expired
- 1973-05-03 ES ES414319A patent/ES414319A1/es not_active Expired
- 1973-05-03 DE DE2322361A patent/DE2322361A1/de not_active Withdrawn
- 1973-05-03 FR FR7315860A patent/FR2183750B1/fr not_active Expired
- 1973-05-04 HU HUME1625A patent/HU165584B/hu unknown
- 1973-05-04 BE BE130744A patent/BE799097A/xx unknown
- 1973-05-04 CH CH636873A patent/CH577989A5/xx not_active IP Right Cessation
- 1973-05-04 ZA ZA733050A patent/ZA733050B/xx unknown
- 1973-05-07 JP JP4989173A patent/JPS5635185B2/ja not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| BE799097A (fr) | 1973-11-05 |
| ZA733050B (en) | 1974-12-24 |
| JPS5635185B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1981-08-15 |
| GB1390486A (en) | 1975-04-16 |
| CA989848A (en) | 1976-05-25 |
| ES414319A1 (es) | 1976-02-01 |
| HU165584B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1974-09-28 |
| NL7305478A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1973-11-07 |
| JPS4961167A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1974-06-13 |
| SE396605B (sv) | 1977-09-26 |
| FR2183750B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1976-03-05 |
| FR2183750A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1973-12-21 |
| AU473061B2 (en) | 1976-06-10 |
| CH577989A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1976-07-30 |
| AU5493873A (en) | 1974-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3709621A1 (de) | Therapeutisches mittel | |
| DE2106209B2 (de) | p-substituierte Phenoxypropanolamine, Verfahren zu deren Herstellung und Arzneimittel auf deren Basis | |
| DE60006810T2 (de) | Dicarboxylato-diamin-platin-derivate und zusammensetzungen die diese als antitumormittel enthalten | |
| EP0236951A2 (de) | Verwendung von Diphenylhydantoin und seinen Derivaten zur Herstellung eines pharmazeutischen Mittels zur Behandlung von Immunerkrankungen | |
| CH634561A5 (de) | Verfahren zur herstellung von neuen 1-nitro-9-dialkylaminoisoalkylaminoacridinen. | |
| DE3109335A1 (de) | Die neue, physiologisch wirksame substanz ebelacton und verfahren zur herstellung derselben | |
| CH630901A5 (de) | Verfahren zur herstellung neuer 1-nitro-9-aminoalkylaminoakridine oder deren salze und gemaess diesem verfahren hergestellte 1-nitro-9-aminoalkylaminoakridine oder deren salze. | |
| DE60203890T2 (de) | Apfelsäureadditionssalze von terbinafin | |
| EP0471388B1 (de) | Mittel zur Behandlung der Herzinsuffizienz | |
| DE2322361A1 (de) | Pyranonderivate und verfahren zu ihrer herstellung | |
| DE2322313A1 (de) | Pyrazolderivate und verfahren zu ihrer herstellung | |
| DE2009685A1 (de) | In 1-Stellung substituierte Derivate von 3,4-Dihydrocarbostyril | |
| AT391699B (de) | Verfahren zur herstellung neuer 4-chloro substituierter furo-(3,4-c)-pyridinderivate | |
| DE2833964A1 (de) | Verfahren zur steigerung der kontraktionsfaehigkeit des herzmuskels | |
| EP0477552A1 (de) | Verwendung von 10-Ring-Lactonen als Lipidregulatoren | |
| DE69328357T2 (de) | Komplex von 2-aminoäthansulfonsäure und zink | |
| EP0121856A2 (de) | Verwendung von Pyrazolonderivaten bei der Bekämpfung des Wachstums von Tumorzellen und der Metastasenbildung, Arzneimittel hierfür und Verfahren zu deren Herstellung | |
| DE2738131A1 (de) | Aminoketone, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
| DE2855306A1 (de) | Mittel zur senkung der herzfrequenz | |
| DE3434562A1 (de) | Verwendung von pyrrothinderivaten | |
| DE2113489B2 (de) | 2-Nitro-benzofuranderivate, ein Verfahren zu deren Herstellung sowie diese Verbindungen enthaltende Arzneimittel | |
| DE1518444C (de) | erythro alpha Phenyl beta amino propanole, Verfahren zu ihrer Herstellung und solche Verbindungen enthaltende Arz neimittel | |
| DE2908032A1 (de) | Acetale und hemiacetale von aminoaldehyden und diese enthaltende therapeutische zubereitungen | |
| DE2810505A1 (de) | Verfahren zur herstellung von isobutyramidderivaten | |
| DE69507113T2 (de) | Therapeutisches Mittel zur Behandlung von ischämischen oder Reperfusion Schädigungen des Myokards |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OD | Request for examination | ||
| 8139 | Disposal/non-payment of the annual fee |